Pulmonary Hypertension

January 25, 2017January 25, 2017

Opsumit Fails to Meet Primary Goal in Phase 3 Trial for PAH-Eisenmenger Syndrome

A Phase 3 trial assessing Actelion‘s Opsumit (macitentan) for the treatment of pulmonary arterial hypertension (PAH) due to Eisenmenger syndrome did not meet its primary objective of a change in exercise ... Read more

January 20, 2017January 20, 2017

PhaseBio’s $14.7M in Financing to Advance Therapy for PAH, Other Cardiopulmonary Disorders

News, Pulmonary Hypertension

PhaseBio Pharmaceuticals has closed on $14.7 million in financing to advance PB1046, its lead compound in clinical development, as a potential treatment of orphan cardiopulmonary disorders such as pulmonary arterial ... Read more

December 19, 2016December 19, 2016

Arena Completes Enrollment in Phase 2 Trial of PAH Therapy Ralinepag

News, Pulmonary Hypertension

Arena Pharmaceuticals completed patient enrollment in its Phase 2 clinical trial evaluating ralinepag (APD811) for the treatment of pulmonary arterial hypertension (PAH). The clinical trial (NCT02279160) first began dosing patients in ... Read more

November 28, 2016November 28, 2016

SteadyMed Launches Website, Social Media Campaign During Pulmonary Hypertension Awareness Month

News, Pulmonary Hypertension

SteadyMed recently announced the launch of BePHenomenal, a new website created to educate and empower people living with pulmonary hypertension (PH), a Thunderclap and a new social media campaign, #PHenomSelf, to recognize “strength ... Read more

November 21, 2016November 21, 2016

Possible PAH Treatment, Now in Testing as Anti-Psychotic, Named Orphan Drug by FDA

News, Pulmonary Hypertension

Reviva Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to RP5063 as a potential treatment of pulmonary arterial hypertension (PAH). The product is already in clinical ... Read more

November 18, 2016November 18, 2016

ProMetic’s Therapy Improved Fibrosis, Cardiac Function in Mice with Heart Failure

News, Pulmonary Hypertension

ProMetic Life Science’s fibrosis-targeting investigational drug PBI-4050 improved pulmonary hypertension (PH), lung remodeling and right ventricular function in mice with heart failure. PBI-4050 also decreased biomarkers for heart disease in patients with ... Read more

November 16, 2016November 16, 2016

Fetal Health Foundation Awards $50,000 to Researcher Working to Treat Birth Defect

News, Pulmonary Hypertension

The Fetal Health Foundation (FHF) named Dr. Jan Deprest the recipient of the 2016 Brianna Marie Memorial Research Grant, a $50,000 award that will be used to further his research ... Read more

October 20, 2016October 20, 2016

#CHEST2016 – Bayer to Present New Data on PAH and Bronchiectasis Therapies

Bronchiectasis, News, Pulmonary Hypertension

Bayer announced it will be giving three oral presentations on lead investigative therapies Adempas (riociguat) for the treatment of pulmonary arterial hypertension (PAH), and ciprofloxacin DPI (dry powder for inhalation) to treat non-cystic ... Read more

October 11, 2016October 11, 2016

First Patient Enrolled in Phase 3 Trial Assessing Bardoxolone Methyl to Treat CTD-PAH

News, Pulmonary Hypertension

Reata Pharmaceuticals announced the enrollment of the first patient in its Phase 3 CATALYST study (NCT02657356) that will evaluate the effectiveness and safety of bardoxolone methyl in patients with connective ... Read more

September 9, 2016September 9, 2016

Study Testing if e-Nose Can Detect Pulmonary Arterial Hypertension by Smelling It

News, Pulmonary Hypertension

Researchers have developed an electronic nose, called e-nose, that may be capable of diagnosing pulmonary arterial hypertension (PAH) by “sniffing” it on a person’s breath. A large study evaluating the ... Read more